Nakao Y, Matsumoto H, Miyazaki T, Watanabe S, Masaoka T, Takatsuki K, Kishihara M, Kobayashi N, Hattori M, Fujita T
Clin Exp Immunol. 1981 Oct;46(1):134-41.
Sera from 244 patients with haematological malignancies were examined for beta 2-microglobulin (beta 2m) levels. There were 142 leukaemias, 32 malignant lymphomas, three immunoblastic lymphomas, two pseudolymphomas and 65 multiple myelomas. Culture supernatants from various established cell lines were also tested. The phenotype facilitating beta 2m shedding from the cell surface appeared to be independent of the specific IgG heavy chain allotypes; however, a myeloma group with normal serum beta 2m levels showed a significant association with the specific Gm allotypes. The determination of serum beta 2m levels can provide valuable information on the proliferative stage of the disorders, the effectiveness of chemotherapy, and be a diagnostic aid for blastic crisis in chronic myelocytic leukaemias, and for subtyping lymphoid malignancies.
检测了244例血液系统恶性肿瘤患者血清中的β2微球蛋白（β2m）水平。其中白血病142例，恶性淋巴瘤32例，免疫母细胞淋巴瘤3例，假性淋巴瘤2例，多发性骨髓瘤65例。还检测了各种已建立细胞系的培养上清液。促进β2m从细胞表面脱落的表型似乎与特定的IgG重链同种异型无关；然而，血清β2m水平正常的骨髓瘤组与特定的Gm同种异型存在显著关联。血清β2m水平的测定可为疾病的增殖阶段、化疗效果提供有价值的信息，并有助于慢性粒细胞白血病急变期的诊断以及淋巴恶性肿瘤的亚型分类。
